Advisory Council on the Implementation of National Pharmacare

Advisory Council on the Implementation of National Pharmacare
Name	Advisory Council on the Implementation of National Pharmacare
Formation	2018
Dissolution	2019
Headquarters	Ottawa
Leader title	Chair
Leader name	Eric Hoskins
Parent organization	Government of Canada

Advisory Council on the Implementation of National Pharmacare

The Advisory Council on the Implementation of National Pharmacare was a federal advisory body created to advise on designing a national prescription drug program in Canada. It operated at the intersection of Canadian public policy debates involving health care reform, drawing on expertise from provincial premiers, academic researchers, and stakeholders linked to health technology assessment and pharmaceutical regulation. The council's work influenced discussions in Parliament, provincial legislatures, and among advocacy organizations.

Mandate and Establishment

The council was established by the Justin Trudeau administration following commitments in the 2015 and 2019 federal platforms to explore a federally supported prescription drug program. Its mandate included providing options for a universal, single-payer or multi-payer model compatible with the Canada Health Act and with provincial frameworks such as those in Ontario, Quebec, British Columbia, and Alberta. The terms of reference asked the council to consider fiscal implications for the Department of Finance (Canada), intergovernmental funding arrangements involving the Council of the Federation, and alignment with regulatory bodies such as Health Canada and the Patented Medicine Prices Review Board. The establishment followed earlier inquiries and commissions including the Romanow Commission, the Kirby Commission, and policy papers from institutions like the Canadian Institute for Health Information and the Fraser Institute.

Membership and Leadership

The council was chaired by Eric Hoskins, a former provincial health minister and executive at Global Affairs Canada-adjacent organizations. Its membership blended former politicians, public servants, academics, and health system executives drawn from organizations such as CIHI, the Canadian Pharmacists Association, and university faculties at institutions including University of Toronto, McGill University, University of British Columbia, and Université de Montréal. Notable members had prior roles with provincial ministries including the Ontario Ministry of Health and Long-Term Care and the Quebec Ministry of Health and Social Services, or affiliations with think tanks like the Canadian Centre for Policy Alternatives and the Munk School of Global Affairs. The council also consulted representatives from national advocacy groups such as Crohn's and Colitis Canada, the Canadian Cancer Society, and the Canadian Federation of Nurses Unions.

Key Reports and Recommendations

In its final report, the council recommended phased implementation steps toward a national formulary, drawing on models from international comparators including the United Kingdom National Health Service, Australia Pharmaceutical Benefits Scheme, and the New Zealand Pharmaceutical Management Agency. It proposed creation of a national formulary governance structure analogous to the National Institute for Health and Care Excellence and suggested pricing reforms coordinated with the Patented Medicine Prices Review Board and procurement mechanisms similar to those used by Ontario Drug Benefit Program and bulk-buying consortia in the European Union. Fiscal recommendations included cost-sharing scenarios with provinces and projections informed by actuarial analyses used by institutions such as the Office of the Parliamentary Budget Officer and the International Monetary Fund. The report emphasized equity principles echoed in rulings and policies tied to the Canada Health Act and referenced legal frameworks under the Charter of Rights and Freedoms in discussions of access and discrimination.

Implementation and Government Response

Following the report, federal ministers including the Minister of Health (Canada) and the Prime Minister of Canada signaled support for incremental action, proposing first-dollar coverage for targeted populations such as seniors and recipients of provincial drug plans. Intergovernmental negotiations involved premiers from provinces like Newfoundland and Labrador, Saskatchewan, and Manitoba, and federal-provincial funding models were debated in forums including the First Ministers' Meeting. Administrative follow-through engaged federal agencies including Health Canada and the Public Health Agency of Canada, while procurement and formulary design consulted pan-Canadian organizations such as the Canadian Agency for Drugs and Technologies in Health. Budgetary implications were considered alongside analyses from the Parliamentary Budget Officer and were influenced by broader fiscal policy decisions by the Department of Finance (Canada).

Criticisms and Controversies

Critics from think tanks and political actors including elements of the Conservative Party of Canada and provincial governments argued the council's recommendations risked federal overreach into provincial jurisdiction, invoking principles from the Constitution Act, 1867 and intergovernmental precedents such as the Fiscal Arrangements Act. Industry groups like Innovative Medicines Canada and some pharmaceutical manufacturers raised concerns about proposed pricing controls and intellectual property implications tied to patents overseen under the Patented Medicine Prices Review Board and international agreements such as the North American Free Trade Agreement and its successor, the Canada–United States–Mexico Agreement. Patient advocacy organizations debated the pace and scope of implementation, while labour organizations including the Canadian Labour Congress and professional associations such as the Canadian Medical Association weighed in on workforce and delivery models. Debates also referenced comparative disputes over pharmacare observed in policy disputes in countries like Germany and France.

Legacy and Impact on Canadian Pharmacare Policy

Though the council was short-lived, its recommendations shaped subsequent federal-provincial dialogues, informed ballot debates involving parties like the New Democratic Party and the Liberal Party of Canada, and influenced policy research at institutions including the Canadian Institute for Health Information and university research centres. Elements of its framework reappeared in provincial initiatives in British Columbia and federal public pharmacare proposals debated in the House of Commons of Canada. The council's emphasis on a national formulary, pooled procurement, and equity-oriented access left a footprint on legislative proposals and on the agenda of health policy organizations such as the Canadian Centre for Policy Alternatives and the Munk School of Global Affairs.

Category:Health policy in Canada Category:Pharmacare